Loading...
Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.
Ugarte-Gil, Manuel Francisco; Mak, Anselm; Leong, Joanna; Dharmadhikari, Bhushan; Kow, Nien Yee; Reátegui-Sokolova, Cristina; Elera-Fitzcarrald, Claudia; Aranow, Cinthia; Arnaud, Laurent; Askanase, Anca D; Bae, Sang-Cheol; Bernatsky, Sasha; Bruce, Ian N; Buyon, Jill; Costedoat-Chalumeau, Nathalie; Dooley, Mary Ann; Fortin, Paul R; Ginzler, Ellen M; Gladman, Dafna D; Hanly, John; Inanc, Murat; Isenberg, David; Jacobsen, Soren; James, Judith A; Jönsen, Andreas; Kalunian, Kenneth; Kamen, Diane L; Lim, Sung Sam; Morand, Eric; Mosca, Marta; Peschken, Christine; Pons-Estel, Bernardo A; Rahman, Anisur; Ramsey-Goldman, Rosalind; Reynolds, John; Romero-Diaz, Juanita; Ruiz-Irastorza, Guillermo; Sánchez-Guerrero, Jorge; Svenungsson, Elisabet; Urowitz, Murray; Vinet, Evelyne; van Vollenhoven, Ronald F; Voskuyl, Alexandre; Wallace, Daniel J; Petri, Michelle A; Manzi, Susan; Clarke, Ann Elaine; Cheung, Mike; Farewell, Vernon; Alarcon, Graciela S
Journal Title
Lupus science & medicine
Readers/Advisors
Journal Title
Term and Year
Publication Date
Book Title
Publication Volume
8
Publication Issue
1
Publication Begin
Publication End
Number of pages
Collections
Files
Research Projects
Organizational Units
Journal Issue
Abstract
In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC) exposure are known to contribute to irreversible organ damage. We aimed to examine the association between GC exposure and organ damage occurrence.
We conducted a literature search (PubMed (Medline), Embase and Cochrane January 1966-October 2021). We identified original longitudinal observational studies reporting GC exposure as the proportion of users and/or GC use with dose information as well as the occurrence of new major organ damage as defined in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Meta-regression analyses were performed. Reviews, case-reports and studies with <5 years of follow-up, <50 patients, different outcomes and special populations were excluded.
We selected 49 articles including 16 224 patients, 14 755 (90.9%) female with a mean age and disease duration of 35.1 years and of 37.1 months. The mean follow-up time was 104.9 months. For individual damage items, the average daily GC dose was associated with the occurrence of overall cardiovascular events and with osteoporosis with fractures. A higher average cumulative dose adjusted (or not)/number of follow-up years and a higher proportion of patients on GC were associated with the occurrence of osteonecrosis.
We confirm associations of GC use with three specific damage items. In treating patients with SLE, our aim should be to maximise the efficacy of GC and to minimise their harms.
We conducted a literature search (PubMed (Medline), Embase and Cochrane January 1966-October 2021). We identified original longitudinal observational studies reporting GC exposure as the proportion of users and/or GC use with dose information as well as the occurrence of new major organ damage as defined in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Meta-regression analyses were performed. Reviews, case-reports and studies with <5 years of follow-up, <50 patients, different outcomes and special populations were excluded.
We selected 49 articles including 16 224 patients, 14 755 (90.9%) female with a mean age and disease duration of 35.1 years and of 37.1 months. The mean follow-up time was 104.9 months. For individual damage items, the average daily GC dose was associated with the occurrence of overall cardiovascular events and with osteoporosis with fractures. A higher average cumulative dose adjusted (or not)/number of follow-up years and a higher proportion of patients on GC were associated with the occurrence of osteonecrosis.
We confirm associations of GC use with three specific damage items. In treating patients with SLE, our aim should be to maximise the efficacy of GC and to minimise their harms.
Citation
Ugarte-Gil MF, Mak A, Leong J, Dharmadhikari B, Kow NY, Reátegui-Sokolova C, Elera-Fitzcarrald C, Aranow C, Arnaud L, Askanase AD, Bae SC, Bernatsky S, Bruce IN, Buyon J, Costedoat-Chalumeau N, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly J, Inanc M, Isenberg D, Jacobsen S, James JA, Jönsen A, Kalunian K, Kamen DL, Lim SS, Morand E, Mosca M, Peschken C, Pons-Estel BA, Rahman A, Ramsey-Goldman R, Reynolds J, Romero-Diaz J, Ruiz-Irastorza G, Sánchez-Guerrero J, Svenungsson E, Urowitz M, Vinet E, van Vollenhoven RF, Voskuyl A, Wallace DJ, Petri MA, Manzi S, Clarke AE, Cheung M, Farewell V, Alarcon GS. Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci Med. 2021 Dec;8(1):e000590. doi: 10.1136/lupus-2021-000590. PMID: 34930819; PMCID: PMC8689160.